AHA 2024 Insights: Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects from the Open Label Extension Trial

186 views
November 25, 2024
Comments 0
Login to view comments. Click here to Login